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This case describes evidence for a Shiga toxin–producing
Escherichia coli (STEC) O146:H28 infection leading to he-
molytic uremic syndrome in a neonate. STEC O146:H28
was linked hitherto with asymptomatic carriage in humans.
Based on strain characteristics and genotyping data, the
mother is a healthy carrier who transmitted the STEC during
delivery. STEC strains belonging to the low-pathogenic
STEC group must also be considered in the workup of neo-
natal hemolytic uremic syndrome.
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The hemolytic uremic syndrome (HUS) is a rare and severe
thrombotic microangiopathy (TMA) characterized by the
triad of hemolytic anemia, thrombocytopenia, and acute renal
failure. In >90% of cases, the disease is triggered by an infec-
tion with Shiga toxin–producing Escherichia coli (STEC) har-
boring speciﬁc Shiga toxin (Stx) 2 subtypes and the adhesion
factor intimin and often presents with a prodromal bloody di-
arrhea. In particular, children between 2 and 6 years of age
are sensitive to the development of the disease. This HUS is
called typical HUS or STEC-HUS [1]. Non-STEC-HUS or
atypical HUS (aHUS) is seen in 5%–10% of all HUS cases and
can appear at any age and may be sporadic or familial. The
majority of cases of a HUS are caused by a disorder in com-
plement alternative pathway regulation and aHUS is often
used to make referral to this particular subgroup [2].
Diagnosis of aHUS relies on (1) no associated disease, (2)
no criteria for STEC-HUS, and (3) no criteria for thrombotic
thrombocytopenic purpura (TTP). Even aHUS and TTP
overlap clinically and morphologically; the discovery of the
speciﬁc involvement of ADAMTS13 (a disintegrin and metal-
loproteinase with a thrombospondin type 1 motif, member
13) in the pathogenesis of TTP allows discrimination between
the 2 TMAs: in patients with TTP, ADAMTS13 activity is
greatly reduced (5%–10% of normal) [3].
Neonatal cases of HUS are predominantly related to aHUS
(in particular metabolic diseases like cobalamin C disorders);
yet, neonatal cases of HUS due to Shiga toxin–producing
E. coli have been anecdotally reported [4, 5].
We describe the case of a newborn boy presenting with HUS
associated with a low-pathogenic STEC. Genetic analyses of the
STEC strains were able to clarify the route of infection.
CASE REPORT
A male newborn (weight: 3680 g, 50th centile; length: 52 cm,
50th–90th centile; head circumference: 34 cm, 10th centile)
was born vaginally by a healthy mother at 41 2/7 weeks of
gestation after a normal pregnancy. Neonatal adaptation was
normal (Apgar score: 7/9/10) and ﬁrst micturition and meco-
nium were unremarkable in the ﬁrst 24 hours of life. Two
days after birth, the newborn displayed relapsing biliary vom-
iting in absence of diarrhea or blood-stained stool losses.
Ileus, volvulus, and malrotation were ruled out by abdominal
radiography and ultrasound. Laboratory investigations did not
show signs of infection or an underlying metabolic disease.
Vomiting stopped spontaneously after 48 hours; oral feeding
was restarted and well tolerated.
At day 6 of life, a sudden increase of bilirubin (total bilirubin:
374 μmol/L, conjugated bilirubin: 42 μmol/L, normal values
<4 μmol/L) was observed and phototherapy started. Further
laboratory investigations revealed the presence of TMA with
hemolytic anemia (hemoglobin, 111 g/L [normal range, 137–
205 g/L]; lactate dehydrogenase, 2223 IU/L [normal value,
<976 IU/L]; fragmentocytes), thrombocytopenia (39 G/L
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[normal range, 100–400 G/L]), and acute renal failure (creati-
nine, 101 μmol/L [normal value, <78 μmol/L]; urea, 16 mmol/
L [normal range, 1.4–6.8 mmol/L]). Urinalysis showed patho-
logically increased proteinuria and hematuria, and blood pres-
sure was within the normal range. Twenty-four hours later,
the newborn developed several episodes of epileptic seizures,
which were successfully treated with phenobarbital and topira-
mate. Cerebral ultrasound was normal and electroencephalog-
raphy registered multifocal epileptogenic activity.
Because the newborn did not show any additional deterio-
ration of renal function and recovered quickly with normaliza-
tion of the hematological and renal parameters together with
stable neurological condition without seizures within 48
hours, renal replacement therapy, plasma exchange, or the
monoclonal antibodies against terminal complement protein
C5 eculizumab were not prescribed.
Testing for causes of atypical HUS and TTP (metabolic,
complement factors, and ADAMTS13 activity) remained neg-
ative. Yet, fecal analysis disclosed the presence of STEC, thus
permitting the diagnosis of typical HUS. Family history was
negative for renal diseases, parents are not consanguineous,
and neither parent had gastrointestinal symptoms during the
previous 3 weeks.
At the 11th day of life, the newborn was discharged from
hospital in good general condition and with normal laboratory
ﬁndings. Antiepileptic therapy with phenobarbital and topira-
mate was tapered during the next 3 months. Within the last 9
months of follow-up, hematological and renal parameters re-
mained within normal range, and the somatic and neurologi-
cal development was unremarkable.
MICROBIOLOGICAL ANALYSIS
Stool samples from the boy and the mother were negative for
Salmonella, Campylobacter, and Shigella by standard bacteriol-
ogy [6] but positive by using an enzyme immunoassay (Pro-
SpecT Shiga Toxin E. coli test; Remel, Lenexa, Kansas) as well
as multiplex polymerase chain reaction (PCR) analysis (E. coli
DEC Primer Mix, Statens Serum Institut, Copenhagen,
Denmark) for STEC.
For the isolation of STEC strains, the stool samples were
streaked onto MacConkey agar, and, after incubation at 37°C
for 24 hours, colonies were washed off with 2 mL of 0.85%
saline solution and tested by colony dot-blot hybridization with
Shiga toxin DNA probes as described by Kaufmann et al [7].
One isolate per sample, corresponding to colored spots, was
picked from the hybridization plate, grown at 37°C overnight
on sheep blood agar, and conﬁrmed as STEC.
Serotyping of the strains was performed with O (O1 to
O186) and H (H1 to H56) speciﬁc rabbit antisera produced at
the Federal Institute for Risk Assessment in Germany.
Shiga toxin genes were subtyped by PCR according to a
standard procedure proposed by the World Health Organiza-
tion Collaborating Centre for Reference and Research on Es-
cherichia and Klebsiella (http://www.ssi.dk). Genes encoding
non–Shiga toxin putative virulence factors of STEC, including
toxins, adhesins, and plasmid-located genes (Table 1), were
detected using a DNA microarray (Identibac E. coli Genotyp-
ing, Alere, Germany).
For genotyping, pulsed-ﬁeld gel electrophoresis (PFGE) was
performed by following the Centers for Disease Control and
Prevention PulseNet protocol using the restriction enzyme
XbaI and the CHEF-DR III system (Bio-Rad Laboratories).
The pulse times were ramped from 5 seconds to 50 seconds
for 19 hours and an angle of 120°. Salmonella Braenderup
strain H9812 (ATCC BAA 664) was used as reference.
RESULTS OF STEC CHARACTERIZATION
The 2 STEC strains isolated from the neonate (strain
N12-0034) and the mother (strain N12-0035) showed a
sorbitol-fermenting STEC serotype O146:H28 that harbored
the virulence gene stx2, but were negative for eae and hlyA.
Selected results for further virulence-associated genes are
Table 1. Presence of Selected Non-stx Putative Virulence
Genes Including Toxins, Adhesins, and Plasmid-Located Genes
for the 2 Shiga Toxin–Producing Escherichia coli Strains Isolated
From a Newborn Boy (N12-0034) and His Mother (N12-0035)
Gene Description
N12-0034
(Neonate)
N12-0035
(Mother)
EHEC-hlyA EHEC hemolysin − −
astA Heat-stable
enterotoxin 1
+ +
cdtB Cytolethal
distending toxin B
− −
eae Intimin − −
iha Iron-regulated gene
A homologue
adhesion
+ +
efa-1 EHEC factor for
adherence
− −
saa Auto agglutinating
adhesin
− −
lpfA Long polar fimbriae + +
bfpA Major subunit of
bundle-forming
pili
− −
katP Catalase-peroxidase − −
espP Serine protease − −
etpD Type II secretion
system
− −
+, the gene is present; −, the gene is absent.
Abbreviation: EHEC, enterohemorrhagic Escherichia coli.
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summarized in Table 1. Both strains produced Shiga toxin as
detected by the enzyme-linked immunosorbent assay. Typing
the stx2 genes revealed for both strains the variant stx2b. In
addition, the strains of the mother and her neonate were indis-
tinguishable in the PFGE analysis.
DISCUSSION
We describe clinical evidence for an STEC O146:H28 infection
leading to HUS in a neonate at the sixth day of life. STEC
O146:H28 was linked so far with asymptomatic carriage in
humans [8, 9].
Pathogenicity of STEC is associated with various virulence
factors, the most important of which are the Shiga toxins.
These toxins can be subdivided into 2 main groups, Stx1 and
Stx2 [10]. STEC strains pathogenic for humans tend to feature
Stx2 and other virulence traits as the adhesion factor
intimin [11]. Of the 7 Stx2 variants described so far, the repre-
sentatives of the Stx2acd group (stx2a, stx2c, stx2d), which are
genetically closely related, are reported to be strongly associat-
ed with HUS in patients [11, 12]. The isolated strains,
however, harbored the variant stx2b and were eae negative,
which has been linked with mild clinical signs or asymptomat-
ic carriage [13, 14].
The mother had no gastrointestinal symptoms and the
newborn presented with vomiting without diarrhea 4 days
before developing hemolytic anemia and renal failure. Based
on the strain characteristics and the genotyping data, we pos-
tulate that the mother is a healthy carrier, who transmitted
the STEC by the fecal-oral route to the newborn during deliv-
ery. In a newborn’s sterile bowel, this STEC may be able to
proliferate and lead to HUS.
In newborns presenting with HUS, it is important to rule
out all causes that can lead to atypical HUS. Even though in-
fectious HUS is a very rare condition in this age group, the
search for this entity is mandatory. STEC strains belonging to
the low-pathogenic STEC group should also be considered.
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